| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Immunology,
Molecular Biotechnology,
Microbiology, and
§
Pathology, University of Washington, Seattle, WA 98195; and
¶
Molecular Immunology Center, University of Texas Southwestern Medical Center, Dallas, TX 75235
We have cloned a TNFR family member from a follicular dendritic
cell (FDC)-like cell line, FDC-1. This molecule, FDC-derived receptor-1
(FDCR-1), is identical to osteoprotegerin (OPG), a soluble cytokine
that regulates osteoclast differentiation. Recently, OPG/FDCR-1 has
been characterized as a second receptor for receptor activator of
NF-
B ligand (RANKL)/TNF-related activation-induced cytokine
(TRANCE), a primarily T-cell restricted TNF family member that augments
dendritic cell (DC) function. In this report, we demonstrate that
OPG/FDCR-1 is membrane bound on the surface of transfected baby hamster
kidney (BHK) and untransfected FDC-1 cells. We also found a restricted
OPG/FDCR-1 expression pattern in lymphoid cells, specifically in B
cells, DCs and FDC-enriched fractions, which in B cells and DCs is
up-regulated by CD40 stimulation. Because OPG/FDCR-1 shares some
properties with RANK, the first RANKL/TRANCE receptor, we discuss how
the balance between RANK and OPG/FDCR-1 expression could influence
immune responses and, ultimately, germinal center
formation.
This article has been cited by other articles:
|
|
 |
|
  T. Chino, K. E. Draves, and E. A. Clark Regulation of dendritic cell survival and cytokine production by osteoprotegerin J. Leukoc. Biol., October 1, 2009; 86(4): 933 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. KIANI, K. JOHNSON, C. CHEN, E. DIEHL, H. HU, G. VASUDEVAN, S. SINGH, L. S. MAGDER, S. J. KNECHTLE, and M. PETRI Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis J Rheumatol, October 1, 2009; 36(10): 2224 - 2230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lorenzo, M. Horowitz, and Y. Choi Osteoimmunology: Interactions of the Bone and Immune System Endocr. Rev., June 1, 2008; 29(4): 403 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H K Datta, W F Ng, J A Walker, S P Tuck, and S S Varanasi The cell biology of bone metabolism J. Clin. Pathol., May 1, 2008; 61(5): 577 - 587. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Kearns, S. Khosla, and P. J. Kostenuik Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease Endocr. Rev., April 1, 2008; 29(2): 155 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Stolina, D. Dwyer, M. S. Ominsky, T. Corbin, G. Van, B. Bolon, I. Sarosi, J. McCabe, D. J. Zack, and P. Kostenuik Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses J. Immunol., December 1, 2007; 179(11): 7497 - 7505. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, G. Toraldo, A. Li, X. Yang, H. Zhang, W.-P. Qian, and M. N. Weitzmann B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo Blood, May 1, 2007; 109(9): 3839 - 3848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Munoz-Fernandez, F. J. Blanco, C. Frecha, F. Martin, M. Kimatrai, A. C. Abadia-Molina, J. M. Garcia-Pacheco, and E. G. Olivares Follicular Dendritic Cells Are Related to Bone Marrow Stromal Cell Progenitors and to Myofibroblasts J. Immunol., July 1, 2006; 177(1): 280 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Valverde, T. Kawai, and M.A. Taubman Potassium Channel-blockers as Therapeutic Agents to Interfere with Bone Resorption of Periodontal Disease Journal of Dental Research, June 1, 2005; 84(6): 488 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nagasaki, M. Inaba, S. Jono, Y. Hiura, H. Tahara, K. Shirakawa, N. Onoda, T. Ishikawa, E. Ishimura, and Y. Nishizawa Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function Eur. J. Endocrinol., March 1, 2005; 152(3): 347 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ueland, R. Jemtland, K. Godang, J. Kjekshus, A. Hognestad, T. Omland, I. B. Squire, L. Gullestad, J. Bollerslev, K. Dickstein, et al. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction J. Am. Coll. Cardiol., November 16, 2004; 44(10): 1970 - 1976. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Vidal, P. Serrant, B. Schlosser, P. van den Broek, F. Lorget, and A. Donnet-Hughes Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses Am J Physiol Gastrointest Liver Physiol, October 1, 2004; 287(4): G836 - G844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Bengtsson, E. J. Ryan, D. Giordano, D. M. Magaletti, and E. A. Clark 17{beta}-Estradiol (E2) modulates cytokine and chemokine expression in human monocyte-derived dendritic cells Blood, September 1, 2004; 104(5): 1404 - 1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. H. Lerner NEW MOLECULES IN THE TUMOR NECROSIS FACTOR LIGAND AND RECEPTOR SUPERFAMILIES WITH IMPORTANCE FOR PHYSIOLOGICAL AND PATHOLOGICAL BONE RESORPTION Critical Reviews in Oral Biology & Medicine, March 1, 2004; 15(2): 64 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Grimaud, L. Soubigou, S. Couillaud, P. Coipeau, A. Moreau, N. Passuti, F. Gouin, F. Redini, and D. Heymann Receptor Activator of Nuclear Factor {kappa}B Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis Am. J. Pathol., November 1, 2003; 163(5): 2021 - 2031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Okuma, K. P. Dalton, L. Buonocore, E. Ramsburg, and J. K. Rose Development of a Novel Surrogate Virus for Human T-Cell Leukemia Virus Type 1: Inhibition of Infection by Osteoprotegerin J. Virol., August 1, 2003; 77(15): 8562 - 8569. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Ahuja, S. Zhao, T. Bellido, L. I. Plotkin, F. Jimenez, and L. F. Bonewald CD40 Ligand Blocks Apoptosis Induced by Tumor Necrosis Factor {alpha}, Glucocorticoids, and Etoposide in Osteoblasts and the Osteocyte-Like Cell Line Murine Long Bone Osteocyte-Y4 Endocrinology, May 1, 2003; 144(5): 1761 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chagraoui, M. Tulliez, T. Smayra, E. Komura, S. Giraudier, T. Yun, N. Lassau, W. Vainchenker, and F. Wendling Stimulation of osteoprotegerin production is responsible for osteosclerosis in mice overexpressing TPO Blood, April 15, 2003; 101(8): 2983 - 2989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D H. Jones, Y-Y Kong, and J M Penninger Role of RANKL and RANK in bone loss and arthritis Ann Rheum Dis, November 1, 2002; 61(90002): ii32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jono, Y. Ikari, A. Shioi, K. Mori, T. Miki, K. Hara, and Y. Nishizawa Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease Circulation, September 3, 2002; 106(10): 1192 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Cundy, M. Hegde, D. Naot, B. Chong, A. King, R. Wallace, J. Mulley, D. R. Love, J. Seidel, M. Fawkner, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype Hum. Mol. Genet., September 1, 2002; 11(18): 2119 - 2127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schoppet, K. T. Preissner, and L. C. Hofbauer RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 549 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-O. Vidalain, O. Azocar, H. Yagita, C. Rabourdin-Combe, and C. Servet-Delprat Cytotoxic Activity of Human Dendritic Cells Is Differentially Regulated by Double-Stranded RNA and CD40 Ligand J. Immunol., October 1, 2001; 167(7): 3765 - 3772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. S. Browner, L.-Y. Lui, and S. R. Cummings Associations of Serum Osteoprotegerin Levels with Diabetes, Stroke, Bone Density, Fractures, and Mortality in Elderly Women J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 631 - 637. [Abstract] [Full Text]
|
|
|
|
|
|
T. J. Yun, M. D. Tallquist, A. Aicher, K. L. Rafferty, A. J. Marshall, J. J. Moon, M. K. Ewings, M. Mohaupt, S. W. Herring, and E. A. Clark Osteoprotegerin, a Crucial Regulator of Bone Metabolism, Also Regulates B Cell Development and Function J. Immunol., February 1, 2001; 166(3): 1482 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Wang, L. Zhang, X. Zhang, J. Moreno, X. Luo, M. Tondravi, and Y. Shi Differential Regulation of the Expression of CD95 Ligand, Receptor Activator of Nuclear Factor-{{kappa}}B Ligand (RANKL), TNF-Related Apoptosis-Inducing Ligand (TRAIL), and TNF-{{alpha}} During T Cell Activation J. Immunol., February 1, 2001; 166(3): 1983 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.A. Taubman and T. Kawai Involvement of T-Lymphocytes in Periodontal Disease and in Direct and Indirect Induction of Bone Resorption Critical Reviews in Oral Biology & Medicine, January 1, 2001; 12(2): 125 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Grcevic, S.-K. Lee, A. Marusic, and J. A. Lorenzo Depletion of CD4 and CD8 T Lymphocytes in Mice In Vivo Enhances 1,25-Dihydroxyvitamin D3-Stimulated Osteoclast-Like Cell Formation In Vitro by a Mechanism That Is Dependent on Prostaglandin Synthesis J. Immunol., October 15, 2000; 165(8): 4231 - 4238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hofbauer and A. E. Heufelder The Role of Receptor Activator of Nuclear Factor-{kappa}B Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2355 - 2363. [Full Text]
|
|
|
|
|
|
I Itonaga, A Sabokbar, D W Murray, and N A Athanasou Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages Ann Rheum Dis, January 1, 2000; 59(1): 26 - 31. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. C. Dougall, M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De Smedt, E. Daro, J. Smith, M. E. Tometsko, C. R. Maliszewski, et al. RANK is essential for osteoclast and lymph node development Genes & Dev., September 15, 1999; 13(18): 2412 - 2424. [Abstract] [Full Text]
|
|
|
|
 |
|
 U. M. Malyankar, M. Scatena, K. L. Suchland, T. J. Yun, E. A. Clark, and C. M. Giachelli Osteoprotegerin Is an alpha vbeta 3-induced, NF-kappa B-dependent Survival Factor for Endothelial Cells J. Biol. Chem., July 7, 2000; 275(28): 20959 - 20962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schoppet, K. T. Preissner, and L. C. Hofbauer RANK Ligand and Osteoprotegerin: Paracrine Regulators of Bone Metabolism and Vascular Function Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 549 - 553. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
